Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery systems has expanded its long-standing collaboration with Catalent, the US-based leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to include the provision and accelerated delivery of advanced visual inspection systems to help with potential solutions to the pandemic.
Stevanato Group’s integrated capabilities serving the pharma industry and its proven expertise in visual inspection will allow the company to support Catalent and its customers’ biologics and sterile injectable products.
Within the context of an expanded partnership, Catalent has ordered Plus 400 LKD automatic and PWL semi-automatic visual inspection machines from Stevanato Group. Catalent will install the equipment at its sites in Bloomington, Indiana, and Anagni, Italy, to support various customer programs. The quality assurance solutions feature advanced technologies to reliably inspect biologics and sterile injectables, maximizing the detection rate while keeping false rejects low. A nod to the expediency required in the current environment, Stevanato Group is accelerating delivery of the high precision and high throughput equipment by several months.
“Catalent appreciates Stevanato Group’s commitment to delivering these vital inspection machines to our sites ahead of schedule,” said Dominick Marino, Vice President of Global Procurement at Catalent. “This added capability will increase the speed in which we package and supply important medicines for our customers and patients.”
“We understand what is at stake, and our engineers are committed to delivering high-performance inspection machines ahead of schedule to meet Catalent’s needs and expectations,” said Raffaele Pace, Engineering Vice President of Operations, Stevanato Group.